KOGLUCOID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KOGLUCOID (KOGLUCOID).
KOGLUCOID (velaglucerase alfa) is a recombinant form of human glucocerebrosidase, which catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. It replaces the deficient enzyme in patients with Gaucher disease, reducing accumulation of glucocerebroside in macrophages.
| Metabolism | Degraded via catabolism into small peptides and amino acids; no specific metabolic pathway identified. |
| Excretion | KOGLUCOID (velaglucerase alfa) is a recombinant human glucocerebrosidase used for Gaucher disease. It is a protein therapeutic; elimination occurs via catabolism (proteolysis) to small peptides and amino acids. No significant renal or biliary excretion of intact drug. <1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is approximately 15-30 minutes (range 11-35 min) in plasma after IV infusion. Short half-life necessitates frequent dosing (every 2 weeks). This reflects rapid clearance via receptor-mediated uptake into macrophages. |
| Protein binding | Approximately 25-35% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). Binding is moderate and non-saturable at therapeutic concentrations. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 0.08-0.15 L/kg, indicating distribution primarily within the vascular and extracellular spaces. This is consistent with a large protein that does not extensively penetrate tissues except via receptor-mediated uptake in target cells (macrophages). |
| Bioavailability | Only administered intravenously. Bioavailability is 100% by IV route. Not available orally (degraded in GI tract). |
| Onset of Action | Intravenous: Pharmacodynamic effects (increase in hemoglobin, platelet count, and reduction in organomegaly) are observed after 3-6 months of regular dosing. No immediate clinical effect. |
| Duration of Action | Duration of action is limited to the interval between infusions (2 weeks). Enzyme replacement therapy is required lifelong to maintain clinical benefit due to rapid clearance and ongoing substrate accumulation. |
60 U/kg intravenously over 4 hours every 2 weeks.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific dosage adjustments for hepatic impairment; use with caution in severe hepatic disease. |
| Pediatric use | Weight-based dosing: 60 U/kg intravenously over 4 hours every 2 weeks; for children <2 years, safety and efficacy not established. |
| Geriatric use | No specific dosage adjustments recommended; clinical studies included limited number of patients ≥65 years, no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KOGLUCOID (KOGLUCOID).
| Breastfeeding | Excretion of velaglucerase alfa into human milk is unknown. Because many drugs are excreted in human milk, caution should be exercised when KOGLUCOID is administered to a nursing woman. The molecular weight (approximately 63 kDa) suggests that passage into breast milk is limited. No M/P ratio is available. |
| Teratogenic Risk | KOGLUCOID (velaglucerase alfa) is a recombinant glucocerebrosidase used for Gaucher disease. There are no adequate and well-controlled studies in pregnant women. Animal studies with velaglucerase alfa at doses up to 15 mg/kg (27 times the human steady-state AUC at 60 U/kg) did not reveal evidence of fetal harm. However, because animal reproduction studies are not always predictive of human response, the drug should be used during pregnancy only if clearly needed. Available postmarketing data are insufficient to determine drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. |
■ FDA Black Box Warning
None
| Serious Effects |
["Patients with life-threatening hypersensitivity to velaglucerase alfa or any excipients"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis have been reported; appropriate medical support should be available.","Administration of KOGLUCOID may result in severe allergic or hypersensitivity reactions.","Patients should be monitored for infusion-related reactions."] |
Loading safety data…
| Fetal Monitoring | Monitor pregnant women with Gaucher disease for disease progression (e.g., hepatosplenomegaly, bone pain, cytopenias) and adjust dose as needed. Fetal monitoring includes ultrasound for growth and anatomy. No specific fetal monitoring requirements are mandated by the drug. |
| Fertility Effects | No clinical studies have been conducted to evaluate the effect of KOGLUCOID on fertility. In animal studies, velaglucerase alfa administered intravenously to female rats at doses up to 15 mg/kg (27 times the human steady-state AUC at 60 U/kg) had no effect on fertility or mating performance. Male fertility was not evaluated in animals. |